Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

Modeling Genetic Circuitry of Cell-To-Cell Communication with Integrated Fluid Circuit Technology

By BiotechDaily International staff writers
Posted on 26 Aug 2010
Utilizing integrated fluidic circuits (IFCs), researchers have discovered a much larger spectrum of differences between individual cells than has previously been demonstrated. Among these differences are the communication capabilities that emerge from the interactions of genetic circuitry that mediates cell-to-cell communication.

Stanford University (Palo Alto, CA, USA) investigators used Fluidigm Corporation's (South San Francisco, CA, USA) Dynamic Array and Digital Array technology in addition to support instrumentation for its cell culture chip as part of this innovative analysis and modeling on how biologic systems operate at the cellular level.

Stanford University School of Medicine found that, "Cells don't all act in a uniform fashion, as was previously thought. Think of cells as musicians in a jazz band,” said Marcus Covert, Ph.D., assistant professor of bioengineering and senior author of the study, published online in the journal Nature June 27, 2010. Dr. Covert's lab studies complex genetic systems. "One little trumpet starts to play, and the cells go off on their own riffs. One plays off of the other.”

Up to now, most of the scientific data collected on cell signaling has been obtained from populations of cells using bulk assays due to technologic limitations on the ability to examine each individual cell. The new study, using an imaging system developed at Stanford based on microfluidics, revealed that scientists have been misled by the results of the cell-population-based studies, according to the researchers.

"This study represents a triple-play of Fluidigm capabilities. Steve, Markus, and their teams used Fluidigm's Dynamic Arrays and Digital Arrays chips for a large portion of their work and some of our analytical instrumentation in operating the cell culture chip. Their work with cell culture coincides with development work that Fluidigm has underway to develop a Stem Cell Culture Chip for the commercial market under a grant from CIRM [California Institute of Regenerative Medicine],” said Gajus Worthington, president and chief executive officer of Fluidigm.

Fluidigm provides commercially available technology on the market to examine individual cells. This technology enabled these Stanford researchers to look at thousands of individuals cells and conduct a multitude of tests on each cell. Fluidigm researchers said, "Population studies have not revealed the intricate network of information one observes at the single-cell level.

"This really surprised us,” said study coauthor Stephen Quake, Ph.D., a professor of bioengineering at Stanford, and a leader in the field of microfluidics. "It sends us back to the drawing board to figure out what is really going on in cells.”

The study used a combination of Fluidigm 48.48 Dynamic Array IFCs to perform 2,304 quantitative polymerase chain reactions (qPCR) in parallel per chip. The cycle thresholds measured during qPCR reactions were converted into relative expression levels and those expression levels were calibrated for total mRNA molecules per cell using Fluidigm Digital Array IFCs performing digital PCR measurements on a single gene.

"These results highlight the value of high-throughput, quantitative measurements, with single-cell resolution in understanding how biological systems operate. We couldn't agree more,” said Fred Walder, Fluidigm's chief business officer. "The Fluidigm platform is uniquely matched to this emerging and critical biological research reality. As more scientists discover that single-cell understanding is key to life science research, we anticipate dramatically increasing interest and demand for our IFC platform products.”

Fluidigm develops, manufactures, and markets proprietary IFC systems that significantly improve productivity in life science research. Fluidigm IFCs enable the simultaneous performance of thousands of sophisticated biochemical measurements in extremely minute volumes. These "integrated circuits for biology” are made possible by miniaturizing and integrating liquid-handling components on a single microfluidic device.

Related Links:

Stanford University
Fluidigm



Channels

Genomics/Proteomics

view channel
Image: The bone marrow of mice with normal ether lipid production (top) contains more white blood cells than are found in the bone marrow of mice with ether lipid deficiency (bottom) (Photo courtesy of Washington University School of Medicine).

Inactivating Fatty Acid Synthase Reduces Inflammation by Interfering with Neutrophil Membrane Function

The enzyme fatty acid synthase (FAS) was shown to regulate inflammation by sustaining neutrophil viability through modulation of membrane phospholipid composition. Neutrophils are the most abundant... Read more

Drug Discovery

view channel
Image: Researchers have attached two drugs—TRAIL and Dox—onto graphene strips. TRAIL is most effective when delivered to the external membrane of a cancer cell, while Dox is most effective when delivered to the nucleus, so the researchers designed the system to deliver the drugs sequentially, with each drug hitting a cancer cell where it will do the most damage (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Anticancer Drug Delivery System Utilizes Graphene Strip Transporters

The ongoing search by cancer researchers for targeted drug delivery systems has generated a novel approach that uses graphene strips to transport simultaneously the anticancer agents TRAIL (tumor necrosis... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Business

view channel

Biotech Acquisition Designed to Accelerate the Development and Marketing of Immunosequencing Applications

Adaptive Biotechnologies Corp. (Seattle, WA, USA), a developer of next-generation sequencing (NGS) to profile T-cell and B-cell receptors, has acquired of Sequenta, Inc. (South San Francisco, CA, USA), which is expected to expedite and expand the use of innovative immunosequencing technology for researchers and clinicians... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.